Fed’s Powell opens door to potential rate cuts at Jackson Hole
On Monday, H.C. Wainwright analyst Robert Burns adjusted the price target for Y-mAbs Therapeutics (NASDAQ:YMAB) stock to $11.00 from the previous $12.00, while reaffirming a Buy rating on the company’s shares. The revision reflects anticipation of upcoming developments that could expand the company’s drug pipeline. According to InvestingPro data, analyst targets for YMAB range from $3 to $26, with the stock currently trading at $4.1. The company’s overall financial health score is rated as GOOD, despite challenging market conditions that have led to a 62% decline over the past six months.
Burns highlighted key events expected to unfold soon, including a detailed update from the Phase 1/2 trial of Y-mAbs’ GD2-SADA program. The update is scheduled for the company’s Research and Development (R&D) day on May 28, 2025. Preliminary data from the trial suggests rapid absorption and clearance of the GD2-SADA within four days, with imaging indicating significant tumor uptake and minimal off-tumor localization.
The analyst also pointed to the swift progress expected in the next phase of the trial, stating that Part B should be completed much faster than Part A. Additionally, Burns noted that updates on nonclinical optimization studies for the GD2-SADA asset and plans for its clinical implementation will be shared at the upcoming R&D day.
Y-mAbs Therapeutics is also set to reveal new potential high-value targets for SADA Pretargeted Radioimmunotherapy (PRIT) and an updated pipeline during the same event. The company has a strategy to consistently file Investigational New Drug (IND) applications annually based on SADA constructs.
Burns reiterated the Buy rating, expressing confidence in the company’s future despite the marginal decrease in the price target. The adjustment to $11 per share from the previous $12 is based on the current and upcoming catalysts that could drive the expansion and success of Y-mAbs’ product portfolio. Based on InvestingPro’s Fair Value analysis, the stock appears undervalued at current levels, though investors should note that five analysts have recently revised their earnings expectations downward. Get access to more detailed insights and 7 additional ProTips with an InvestingPro subscription.
In other recent news, Y-mAbs Therapeutics announced its first-quarter 2025 earnings, reporting an earnings per share (EPS) of -$0.12, which exceeded the forecast of -$0.1911. The company’s revenue was $20.9 million, slightly surpassing the anticipated $20.84 million. Y-mAbs Therapeutics maintained its full-year revenue guidance between $75 million and $90 million, with expectations for Q2 2025 revenue to range from $17 million to $19 million. The company saw an 8% year-over-year revenue increase, largely driven by international sales, despite a decline in U.S. sales. During the earnings call, executives highlighted the ongoing development of their radiopharmaceutical platform and strategic focus on clinical trials. The company also reported a net loss of $5.2 million for the quarter. With cash and cash equivalents totaling $60.3 million, Y-mAbs Therapeutics anticipates its operations will be funded into 2027. Additionally, the company has been focusing on expanding its market presence globally and advancing its clinical trials.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.